Karenitecin (Ovarian Cancer) Analysis and Forecast to 2020


#28299

35pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU and Japan (seven major markets)
  • Analysis and review of Karenitecin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Karenitecin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Karenitecin in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 8


3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13


5 Karenitecin 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Factors Affecting Sales of Karenitecin 17
5.4.1 Good Safety Profile 17
5.4.2 Large Unmet Need 17
5.4.3 Low Efficacy 17
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Intensity of Competition 19
5.6 Sales Forecasts 19
5.6.1 Target Patient Pool of Karenitecin 19
5.6.2 Dosing 20
5.6.3 Market Penetration 20
5.6.4 Annual Cost of Therapy 21
5.7 Sales Projections of Karenitecin 22


6 Ovarian Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abberiviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 33
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 35
6.6 Sources 35


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Drug Risk Benefit Score 18
Table 5: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 22
Table 6: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 23
Table 7: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 24
Table 8: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 25
Table 9: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 26
Table 10: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 27
Table 11: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 28
Table 12: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 29


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of Karenitecin 20
Figure 9: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 22
Figure 10: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 23
Figure 11: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 24
Figure 12: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 25
Figure 13: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 26
Figure 14: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 27
Figure 15: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 28
Figure 16: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 29
Figure 17: Karenitecin , Ovarian Cancer, Sales Distribution (%), By Country, 2020 30
Figure 18: Drug Model Diagram 33
Figure 19: Patients Approved for the Drug 33